Disease relevance of MTBP

• This study demonstrates that the human choriocarcinoma cell line (JEG-3) also contains the MTBP and that in both human placenta and JEG-3 cells the MTBP is located exclusively in the nucleus and in particular is associated with DNase 1 resistant chromatin [1].

High impact information on MTBP

• Regulation of p53 and MDM2 activity by MTBP [2].
• A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2 [3].
• Telomere-binding TRF2/MTBP attaches telomeres to the nuclear envelope in interphase due to its rod-domain-like motif [4].
• The methyltrienolone binding protein (MTBP) found in human placental cytosol was found to require a low molecular weight modulator for steroid binding activity [5].
• Purification and characterization of the modulating activity showed that NAD+ is the endogenous substance responsible for activating MTBP to a form capable of steroid binding [5].

Biological context of MTBP

• Assignment of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridization [6].
• An investigation of the tissue distribution of human MTBP demonstrated that MTBP binding activity was present in placenta and chorion but absent from amnion and umbilical cord [5].

Associations of MTBP with chemical compounds

• Human placenta contains the methyltrienolone binding protein (MTBP), an androgen binding protein which is distinct from the androgen receptor [1].

Physical interactions of MTBP

• Using a yeast two-hybrid screen, we have identified a gene that encodes a novel cellular protein (MTBP) that binds to MDM2 [3].

Other interactions of MTBP

• MTBP can induce G(1) arrest, which in turn can be blocked by MDM2 [3].

References